| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
35 |
| Employees |
650 |
| Revenues (TTM) (Millions $) |
304 |
| Net Income (TTM) (Millions $) |
-181 |
| Cash Flow (TTM) (Millions $) |
-155 |
| Capital Exp. (TTM) (Millions $) |
60 |
Business Description
Amag Pharmaceuticals Inc. is a publicly-traded biopharmaceutical company headquartered in Waltham, Massachusetts. It was founded in 1981 and is focused on developing innovative therapies to improve patients' lives.
Amag Pharmaceuticals Inc. has a diverse product portfolio that includes drugs for the treatment of various medical conditions. The company's core therapeutic areas are women's health, anemia, and cancer supportive care.
One of Amag's flagship products is Makena, a hormone injection used to prevent preterm birth in women who have a history of preterm birth. The company acquired the rights to Makena from Hologic in 2014, and it has been a significant contributor to Amag's revenue since then.
The company also has two FDA-approved drugs, Feraheme and MuGard, that are used to treat iron deficiency anemia and the oral mucositis associated with chemotherapy and radiation, respectively.
In addition to its marketed products, Amag Pharmaceuticals is also engaged in research and development of new medicines. The company has a robust pipeline that comprises several promising drugs at various stages of development.
AMAG-423, for example, is an investigational therapy that is being evaluated for the treatment of severe preeclampsia, a potentially life-threatening pregnancy complication. Another compound, Vyleesi, is a self-administered injection that is being developed to address hypoactive sexual desire disorder in women.
The company's research and development efforts also include exploring the potential of the synthetic lactoferrin protein to treat iron deficiency anemia, as well as innovative technologies for drug delivery and formulation.
Overall, Amag Pharmaceuticals Inc. is a research-driven pharmaceutical company that is committed to developing innovative therapies for significant, unmet medical needs. The company's key strengths lie in women's health, anemia, and cancer supportive care, and it leverages its expertise in these areas to drive innovation and value for patients and investors alike.
Company Address: 1100 Winter Street, Waltham, 2451 MA
Company Phone Number: 498-3300 Stock Exchange / Ticker: NASDAQ AMAG
|
%